Annals of Hepato-Biliary-Pancreatic Surgery

Indexed in /covered by CAS, KoreaScience & DOI/Crossref:eISSN 2508-5859   pISSN 2508-5778

Table. 1.

Table. 1.

Clinico-demographic and pathological comparison between DM and non DM

Variables DM (31) Non DM (110) Total (141) p-value
Age 57.64±9.99 53.21±1.15 54.1±11.73 0.06
Sex
Male 18 (58.1%) 68 (61.8%) 86 (61.0%) 0.70
Female 13 (41.9%) 42 (38.2%) 55 (39.0%)
Pain abdomen 14 (45.2%) 55 (50.0%) 69 (48.9%) 0.63
Jaundice 21 (67.7%) 89 (80.9%) 110 (78.0%) 0.11
Weight loss 20 (64.5%) 77 (70.0%) 97 (68.8%) 0.56
Alcohol 5 (16.1%) 27 (24.5%) 32 (22.7%) 0.32
Smoking 4 (12.9%) 21 (19.1%) 25 (17.7%) 0.42
Preoperative biliary drainage 14 (45.2%) 57 (51.8%) 71 (50.4%) 0.51
Site of tumor
Pancreas* 12 (38.7%) 24 (21.8%) 36 (25.5%) 0.30
Ampulla 9 (29.0%) 39 (35.5%) 48 (34.0%)
Lower third CBD 6 (19.4%) 28 (25.5%) 34 (24.1%)
Duodenum 4 (12.9%) 19 (17.3%) 23 (16.3%)
Surgery performed
Pylorus not preserved 17 (54.8%) 54 (49.1%) 71 (50.35%) 0.57
Pylorus preserved 14 (45.2%) 56 (50.9%) 70 (49.64%)
Mean operative time (min) 366.53±95.1 346.57±80.18 349.57±82.41 0.43
Pancreatic consistency
Soft 8 (29.6%) 33 (35.9%) 41 (34.5%) 0.55
Firm 19 (70.4%) 59 (64.1%) 78 (65.5%)
Dilated MPD 16 (66.7%) 40 (51.3%) 56 (54.9%) 0.18
Vascular repair 1 (3.2%) 4 (3.6%) 5 (3.5%) 0.19
Blood transfusion 5 (16.1%) 21 (19.9%) 26 (18.4%) 0.86
Tumor differentiation
Well 4 (12.9%) 21 (19.1%) 25 (17.7%) 0.57
Moderate 21 (67.7%) 68 (61.8%) 89 (63.1%)
Poor 0 4 (3.6%) 4 (2.8%)
NOS 6 (19.3%) 17 (15.4%) 23 (16.3%)
T stage 28 99 127
1 2 (7.1%) 17 (17.2%) 19 (15.0%) 0.23
2 10 (35.7%) 37 (37.4%) 47 (37.0%)
3 16 (57.1%) 40 (40.4%) 56 (44.1%)
4 0 5 (5.1%) 5 (3.9%)
N stage 29 95 124 0.75
0 15 (51.7%) 57 (60.0%) 72 (58.1%)
1 12 (41.4%) 32 (33.7%) 44 (35.5%)
2 2 (6.9%) 6 (6.3%) 8 (6.5%)
Lymphovascular invasion 6 (19.3%) 25 (22.7%) 31 (21.9%) 0.88
Perineural invasion 5 (16.1%) 21 (19.0%) 26 (18.4%) 0.75
Adjuvant therapy** 15/28 (53.6%) 48/93 (51.6%) 63/121 (52.1%) 0.85
Chemotherapy only 3 (10.7%) 9 (9.7%) 12 (9.9%) 0.87
Radiation only 6 (21.4%) 18 (19.4%) 24 (19.8%) 0.81
Chemoradiation 6 (21.4%) 21 (22.6%) 27 (22.3%) 0.89

DM, diabetes mellitus; Non DM, non diabetes mellitus; CBD, common bile duct; MPD, main pancreatic duct; NOS, not otherwise specified

*Within pancreas as site of tumor, in DM 3 out of 12 cases were periampullary carcinoma (pancreatic origin) and in non DM 5 out of 24 cases were periampullary carcinoma (pancreatic origin)

**Data of adjuvant therapy was available in 121 patients out of 141 patients. Out of these 63 patients received adjuvant therapy

Ann Hepatobiliary Pancreat Surg 2021;25:230-41 https://doi.org/10.14701/ahbps.2021.25.2.230
© 2021 Ann Hepatobiliary Pancreat Surg